Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;22(2):261-268.

miR-30 inhibits the progression of osteosarcoma by targeting MTA1

Aiqing Zhao #  1 , Yanbin Zhao #  2 , Wei Feng  3 , Zhenqun Zhao  4 , Wanlin Liu  4 , Na Wang  5 , Huiqin Xue  6 , Lishuan Wu  5 , Shuxia Cui  5 , Rui Bai  4
Affiliations

miR-30 inhibits the progression of osteosarcoma by targeting MTA1

Aiqing Zhao et al. J Musculoskelet Neuronal Interact. .

Abstract

Objectives: MicroRNAs (miRNAs) have been considered as a new class of novel diagnostic and predictive biomarker in many diseases. However, there are few studies on miRNA in osteosarcoma (OS). This study aimed to investigate the roles of miR-30 on OS occurrence and development.

Methods: PCR was used to detect mRNA levels of miR-30 and MTA1 in cancer tissues, adjacent non-cancerous tissues from OS patients. Western blot was used to detect MTA1 protein expression in all tissues and cell lines (hFOb1.19,Saos-2, MG63, and U2OS). The correlation between miR-30 and MTA1 was predicted through bioinformatics software, and identified by a luciferase reporting experiment. In vitro, functional test detected the specific effects of miR-30 and MTA1 on the development of OS.

Results: miR-30 expression was significantly reduced, while the expression of MTA1 was increased in OS tissues and cells. Luciferase reporting experiment showed that miR-30 sponged MTA1 which was negatively correlated with miR-30 expression. Furthermore, rescue tests revealed that MTA1 restrained the functions of miR-30 on cell proliferation and migration of OS.

Conclusion: Our finding showed that miR-30 modulated the proliferation and migration by targeting MTA1 in OS.

Keywords: MTA1; Osteosarcoma; miR-30.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest.

Figures

Figure 1
Figure 1
miR-30 expression is downregulated in OS tissues and cells. A. miR-30 expression in OS tissues and adjacent tissue. B. miR-30 expression in OS cells. ***P<0.001.
Figure 2
Figure 2
miR-30 suppressed cell proliferation and migration in OS. miR-30 inhibitor, miR-30 mimic and their control were used to transfect into MG63 cells. A. The transfection efficiency of miR-30 inhibitor and miR-30 mimic. B. Cell viability detected through CCK-8 assay. C. Cell proliferation measured through EdU assay. D. Transwell assay assessed cell migration. E. The expression of Ki-67 and E-cad detected by western blot assay. ***P<0.001, **P<0.01.
Figure 3
Figure 3
MTA1 is downstream target gene of miR-30. A. The binding sequence between miR-30 and MTA1. B. Luciferase reporter assay. C. The mRNA expression of MTA1. D. miR-30 expression in the MTA1 OE and sh-MTA1 group. E. MTA1 expression in the miR-30 mimic and miR-30 inhibitor group. F and G. The expression of MTA1 in OS tissues and OS cells. H. Correlation analysis of MTA1 and miR-30 in OS tumor tissues. ***P<0.001, **P<0.01.
Figure 4
Figure 4
MiR-30 regulates the progression of OS by targeting MTA1. A. The expression of miR-30 and MTA1. B. The proliferation determined through EdU assay. C. Cell migration determined through transwell assay. ***P<0.001, **P<0.01, *P<0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Toki S, Yoshimaru T, Matsushita Y, Aihara H, Ono M, Tsuneyama K, Sairyo K, Katagiri T. The survival and proliferation of osteosarcoma cells are dependent on the mitochondrial BIG3-PHB2 complex formation. Cancer Sci. 2021;112(10):4208–4219. - PMC - PubMed
    1. Arabi L, Gsponer JR, Smida J, Nathrath M, Perrina V, Jundt G, Ruiz C, Quagliata L, Baumhoer D. Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma - reasons and consequences. Genes Cancer. 2014;5(1-2):56–63. - PMC - PubMed
    1. Wang X, Qin G, Liang X, Wang W, Wang Z, Liao D, Zhong L, Zhang R, Zeng YX, Wu Y, Kang T. Targeting the CK1alpha/CBX4 axis for metastasis in osteosarcoma. Nat Commun. 2020;11(1):1141. - PMC - PubMed
    1. Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, et al. Survival and prognosis with osteosarcoma:outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36–50. - PMC - PubMed
    1. Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Rédini F, Ory B, Heymann D. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett. 2014;344(2):291–8. - PubMed

Publication types